Risk factors for lipid disorders in systemic lupus erythematosus

Abstract

Systemic lupus erythematosus (SLE) is one of the autoimmune diseases of the connective tissue system with multi-organ involvement. Dyslipidemia in SLE results from the increased risk of cardiovascular diseases typical in the general population. Still, it is exacerbated by inflammation and medications (particularly glucocorticosteroids). In the course of SLE, lipid disorders are related to the disease activity and result from cardiovascular risk factors typical for the general population. During the therapy, it is recommended to control the lipid profile and modify the lifestyle risk factors (implement a properly balanced diet and appropriate physical activity). The role of immunosuppressive and immunomodulating therapy in SLE, which may have a pro-or anti-atherogenic effect, is also emphasized. Thus, the assessment of the dyslipidemia type in this disease is crucial. Proper hypolipemic treatment not only reduces the risk of cardiovascular disease but also affects the survival of patients.

I feel it in my fingers, I feel it in my toes, rheumatism that’s all around me…

“…As a result awareness of atherosclerotic heart disease and strokes among patients suffering from connective tissue diseases attract high attention. To address this Kowynia et al [6] performed an extensive review of the lipid metabolism disturbances in systemic lupus ery thematosus. The problem of premature atherosclerosis and so-called bimodal pattern of mortality with the second peak attributable to atherosclerosis and premature cardiovascular death is a well-known clinical entity since the mid-seventies of the last century.…”